APM
IOVA icon

Avidity Partners Management’s Iovance Biotherapeutics IOVA Stock Holding History

Avidity Partners Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,382,900
Closed -$13.2M – 97
2022
Q3 		$13.2M Sell
1,382,900
-9,400
-0.7% -$108K 0.29% 63
2022
Q2 		$15.4M Sell
1,392,300
-4,650,919
-77% -$60.9M 0.35% 45
2022
Q1 		$101M Buy
6,043,219
+2,263,219
+60% +$35M 2.23% 18
2021
Q4 		$72.2M Buy
3,780,000
+2,317,800
+159% +$51M 1.53% 23
2021
Q3 		$36.1M Buy
+1,462,200
New +$34.5M 0.92% 40
2020
Q4 		– Sell
-799,000
Closed -$26.3M – 110
2020
Q3 		$26.3M Buy
799,000
+60,453
+8% +$1.85M 1.42% 27
2020
Q2 		$20.3M Buy
+738,547
New +$24.3M 1.3% 29

Other funds holding IOVA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return